() ()

Paraneoplastic Syndromes, Available at: my.clevelandclinic.org/health/diseases/17938-paraneoplastic-syndrome. Accessed September 12, 2022.

Palapattu G.S. Kristo B. Rajfer J.

Paraneoplastic syndrome in urologic malignancy: the many faces of renal cell carcinoma.

Rev Urol. 4: 163-170McCullough D.L. Harris R.D.

Renal cell carcinoma (hypernephroma): the great masquerader.

J Med Assoc State Ala. 45: 33-37McDougal W.S. Garrick M.B. et al.

Clinical signs and symptoms of renal carcinoma.

in: Vogelzang N.J. Shipley W.U. Scardino P.T. Comprehensive textbook of genitourinary oncology. Williams and Wilkins, Baltimore (MA): 154-159

Paraneoplastic syndromes in hypernephroma.

Semin Nephrol. 7: 12-30Kim H.L. Belldegrun A.S. Freitas D.G. et al.

Paraneoplastic signs and symptoms of renal cell carcinoma-implications for prognosis.

J Urol. 170: 1742-1746Tsukamoto T. Kumamoto Y. Miyao et al.

Interleukin-6 in renal cell carcinoma.

J Urol. 148: 1778-1782Barrington J.L. Kradjian R.M.

Renal carcinoma.

Saunders, Philadelphia ()Gold P.J. Fefer A. Thompson J.A.

Paraneoplastic manifestations of renal cell carcinoma.

Semin Urol. 14: 216-222

Extrarenal manifestations of renal cell carcinoma.

J Urol. 117: 439-440Loughlin K.R. Gittes R.F.

Serum iron: a tumor marker in renal carcinoma.

Br J Urol. 58: 617-620Yu C.C. Chan K.K. Chen M.T.

Serum iron as tumor marker in renal cell carcinoma.

Eur Urol. 19: 54-58Loughlin K.R. Gittes R.F. Partridge D. et al.

The relationship of lactoferrin to the anemia of renal cell carcinoma.

Cancer. 59: 566-571

Fever and reduced iron. Their interaction as a host defense response to bacterial infection.

Science. 203: 374-376Essen A. Ozein H. Ayhan A. et al.

Serum ferritin: a tumor marker for renal cell carcinoma.

J Urol. 45: 1134-1137

Partin A.W., Criley S.R., Steiner M.S., et al., Serum ferritin as a clinical marker for renal cell carcinoma : influence of tumor volume, Urology, 45 (2), 1995, 211–217.

Kirkali Z. Guzelsay M. Mungan M. et al.

Serum ferritin as a clinical marker for renal cell carcinoma: influence of tumor size and volume.

Urol Int. 62: 21-25Ozen H. Uygur C. Sahin A. et al.

Clinical significance of serum ferritin in patients with renal cell carcinoma.

Urology. 46: 494-498

Erythropoietin production in renal tumors.

Ann Clin Lab Sci. 5: 98-109Ljungberg B. Rasmuson T. Grankuist K.

Erythropoietin in renal cell carcinoma : elevation of its usefulness as a tumor marker.

Eur Urol. 21: 160-163Sufrin G. Mirand E.A. Moore R.H. et al.

Hormones in renal cancer.

J Urol. 117: 433-438Gross A.J. Wolff M. Fandrey W.D.

Prevalence of paraneoplastic erythropoietin production by renal cell carcinoma.

Clin Investig. 72: 337-340

Thrombocytosis as a prognostic factor in patients with renal cell carcinoma: a meta-analysis of literature.

J Cancer Res. 11: 67-72Mandal S.K. Ganguly J. Silk et al.

Renal cell carcinoma with paraneoplastic leucocytosis.

J. Cancer Res Ther. 11: 660Dawson N.A. Barr C.F. Alving B.M.

Acquired dysfibrinogenemia: paraneoplastic syndrome in renal cell carcinoma.

Am J Med. 78: 682-686

Nephrogenic hepatosplenomegaly.

Gastroenterology. 40: 694-696Sharma N. Darr U. Darr A. et al.

Stauffer syndrome: a comprehensive review of the icteric variant of the syndrome.

Cureus. 11 () (): e6032Dourakis S.P. Sinani C. Deutsch M. et al.

Cholestatic jaundice as a paraneoplastic manifestation of renal cell carcinoma.

Eur J Gastroenterol Hepatol. 9: 311-314Chavarriago J. Fakih N. Cantano J. et al.

Stauffer syndrome, clinical implications and knowledge gaps, does size matter? Case report.

BMC Urol. 20: 105-109Fontes-Sausa M. Magalhaes H. da Silva F. et al.

Stauffer’s syndrome: a comprehensive review and proposed updated diagnostic criteria.

Urol Oncol. 36: 321-326

Stauffer’s syndrome in pancrear∖tic cancer: first case report.

Cureus. 9: 5-6Karakolio A. Kasapisa C. Kallinekidisa et al.

Cholestatic jaundice as a paraneoplastic manifestations of prostate adenocarcinoma.

Cline Gastroenterol Hepatol. 6: 480-483Marla D. Alazemi S. Lichstein D.

Stauffer’s syndrome variant with cholestatic jaundice : a case report.

J Gen Intern Med. 21: 11-13Mehta D. Chugh P. Chawla L. et al.

Paraneoplastic hepatology associated with gastrointestinal carcinoma.

ACG Case Rep J. 4: 117-118Tsukamato T. Kumamoto Y. Miyan N. et al.

Interleukin-6 in renal cell carcinoma.

J Urol. 148: 1178-1781Blay J.Y. Rossi J.F. Wijdenes J. et al.

Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal cell carcinoma.

Int J Cancer. 75: 424-430

Cancer-related hypercalcemia.

J Oncol Pract. 12: 426-432Gomes L. Kulak C. Costa T. et al.

Association of primary hyperthyroidism and humoral hypercalcemia of malignancy in a patient with clear cell renal carcinoma.

Arch Endocrinol Metab. 59: 84-88

Hypercalcemia associated with cancer.

N Engl J Med. 352: 372-379

Case records of the Massachusetts General Hospital -Case 39061.

N Engl J Med. 225: 789-796

Overview of cancer-related hypercalcemia: epidemiology and etiology.

Semin Oncol. 17: 3-9Warren W.D. Utz D.C. Kelalis P.P.

Concurrence of hypernephroma and hypercalcemia.

Ann Surg. 174: 863-865Murdy G.R. Ibbotson K.J. D’Suza S.M. et al.

The hypercalcemia of cancer.

N Engl J Med. 310: 1718-1727Buckner R.M. McMillian M. Mallinson C.

Ectopic secretion of parathyroid hormone by a renal adenocarcinoma in a patirnt with hypercalcemia.

Br Med J. 4: 724-726Plimpton C.H. Gellhorn A.

Hypercalcemia in malignant disease without evidence of bone destruction.

Am J Med. 21: 750-759Chason S.A. Pothel R.L. Huben R.P.

Management and prognostic significant of hypercalcemia in renal cell carcinoma.

Urology. 33: 167-171

Hypercalcemia of malignancy. An update on pathogens and management N.

Am J Med Sci. 7: 483-493

Hypercalcemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone.

Endocr Relat Cancer. 12: 549-585Seyberth H.W. Segre G.V. Morgan J.L. et al.

Prostaglandins as mediators of hypercalcemia associated with certain types of cancer.

N Engl J Med. 293: 1278-1283Newman N.J. Bell I.R. McKee A.C.

Paraneoplastic limbic encephalitis: neuropsychiatric presentation bio.

Psychology. 27: 529-542Bell B. Tognomi P.G. Bihrle R.

Limbic encephalitis as a paraneoplastic manifestation of renal cell carcinoma.

J Urol. 160: 828Kararizou E. Markov I. Zalonis I. et al.

Paraneoplastic limbic encephalitis presenting as acute viral encephalitis.

J Neurooncol. 75: 229-232Palgon N. Greenstein F. Noretsky A.D. et al.

Hyperglycemia associated with renal cell carcinoma.

Urology. 28: 516-517Vigliani M.C. Palmucci L. Polo P. et al.

Paraneoplastic opsoclonus-myoclones associated with renal cell carcinoma and responsive to tumor ablation carcinoma and responsive to tumor ablation.

J Neurol Neurosurg Psychiatry. 70: 814-815Koukoulis A. Cimas I. Gomaras S.

Paraneoplastic opsoclonus associated with papillary renal cell carcinoma.

J Neurol Neurosurg Psychiatry. 64: 137-138DeLuca S. Terrane C. Crivellaro S. et al.

Opsoclonous-mypclonus syndrome as a paraneoplastic manifestation of renal cell carcinoma.

Urol Int. 68: 206208Torgerson E.L. Khalil R. Dobkin B.H. et al.

Myasthemia gravis as a paraneoplastic syndrome associated with renal cell carcinoma.

J Urol. 162: 154Evans B.K. Fagan C. Arnold et al.

Paraneoplastic moter neuron disease and renal cell carcinoma.

Neurologgy. 40: 960-962Thomas N.E. Passamonte P.M. Sunder Rajan E.V. et al.

Bilateral diaphragmatic paralysis as a possible paraneoplastic syndrome from renal cell carcinoma.

Am Rev Respir Dis. 129: 507-509

Paraneoplastic limbic encephalitis cured with nephron-sparing surgery in a patient with clear cell carcinoma: a case report.

J Int Med Res. 47: 5318-5322Corven C.B. Khala F.A. Courville P. et al.

Renal chromophobe cell carcinoma and paraneoplastic IgA bullous dermatosis.

J Urol. 169: 270Sacco E. Pinto F. Sasso F. et al.

Paraneoplastic syndromes in patients with urological malignancies.

Urol Int. 83: 1-11Moscardi L.|J.L. Macedo N.A. Espasandin J.A. et al.

Malignant acanthosis migraines associated with a renal tumor.

Int J Dermatol. 32: 893-894Jobe B.A. Bierman M.H. Mezzacappa F.J. et al.

Hyperglycemia as a paraneoplastic endocrinopathy in renal cell carcinoma.

Nebr Med J. : 349-351Dilenno N. Han E. Maritland C. et al.

Hypoglycemia in renal cell carcinoma: a rare paraneoplastic syndrome.

Urology. 124: 10-13Philips L.S. Roberston D.G.

Insulin-like growth factors and non-islet cell tumor hypoglycemia.

Metabolism. 42: 1093-1101

Small is beautiful: Insulin-like growth factors and their role in growth development and cancer.

J Clin Oncol. 28: 4985-4995Wurzer H. Brandstatter G. Harnoncourt K. et al.

Paraneoplastic polymyositis associated with a renal carcinoma.

J Intern Med. 234: 521-524Solon A.A. Gilbert C.S. Meyer C.

Myopath as a paraneoplastic manifestation of renal cell carcinoma.

Am J Med. 97: 491-492Algune E. Alici S. Topal C. et al.

Coexistence of subacute thyroiditis and renal cell carcinoma: a paraneoplastic syndrome.

CMAJ. 168: 985-986

Hypertension due to hypernephroma.

Br Med J. 4: 87-89

Association of Cushing’s syndrome and neoplastic disease.

Arch Intern Med. 108: 841-849Fischer K. Thail G. Hoda R. et al.

Serum amyloid: a biomarker for renal cancer.

Anticancer Res. 32: 1801-1804